A Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination With Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer

NCT01311050 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 46

Last updated 2011-12-13

No results posted yet for this study

Summary

A Phase I-II Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination with Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer

Conditions

Interventions

DRUG

Capecitabine (Xeloda), Oxaliplatin, Irinotecan, Bevacizumab

Capecitabine (Xeloda), Oxaliplatin, Irinotecan, Bevacizumab

Sponsors & Collaborators

  • King Faisal Specialist Hospital & Research Center

    lead OTHER

Principal Investigators

  • Shouki Bazarbashi, M.D. · KFSH & RC

Eligibility

Min Age
14 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31

Countries

  • Saudi Arabia

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01311050 on ClinicalTrials.gov